USPTO grants a provisional patent to INVENT Pharmaceuticals' Alzheimer’s drug

American Diversified Holdings Corporation (Pink Sheets: ADHC) Strategic Alliance partner INVENT Pharmaceuticals, Inc. announced today that the U.S. Patent and Trademark Office has granted its provisional patent application US 61/271,720 on novel drug candidates for the treatment of Alzheimer’s disease and age-related cognitive and memory impairment. Alzheimer’s disease is a progressive neurological disorder affecting nearly 37 million people worldwide. The estimated overall annual cost of patient care in the US alone is over $100 billion with over $5 billion in pharmaceutical costs. More than half of the individuals over age 85 and one in ten over age 65 will suffer from Alzheimer’s disease and related cognition and memory dysfunction. Alzheimer’s disease is the gradual loss of cognitive function related to memory, reasoning, judgment and orientation.

Dr. Dale Dhanoa, Ph.D., President and CEO of INVENT Pharmaceuticals stated that “this provisional patent is the first of many that will be granted on drug candidate compounds we have developed. The Company’s proprietary site-specific drug design and discovery platform which is broadly applicable to virtually any molecular drug development target including G-protein coupled receptors, protease enzymes and protein kinases. INVENT has several more pending U.S. and foreign patent applications that will be discussed in the near future.”